Home
Download Center
Case Study
pixlbio wild-type pixHep models tell hepatotoxic drugs from their liver-safe analogues

pixlbio wild-type pixHep models tell hepatotoxic drugs from their liver-safe analogues

Case Study
November 19, 2026
pixlbio wild-type pixHep models tell hepatotoxic drugs from their liver-safe analogues
grid

Discriminating a hepatotoxic drug from its structurally related, liver-safe analogue is one of the most stringent tests for a liver-safety model. As part of a 3Rs Collaboration and FDA CDER initiative, we tested wild-type iPSC-derived pixHep against four blinded matched pairs. Cells were dosed at 0.01x to 10x Cmax for 10 days and assessed on morphology, albumin secretion, AST release, ATP content and CYP3A4 activity. pixHep correctly separated every High-DILI compound from its Low-DILI analogue, including troglitazone vs pioglitazone and tolcapone vs entacapone. Five complementary endpoints provided a mechanistic profile rather than a single toxicity readout, supporting early, animal-free de-risking of drug candidates.

Download Resource
Download this resource to access the complete set of materials, insights, and supporting information related to this topic.
Other Resources

Other Resources You Might Also be Interested in